THE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONS
Despite progress in reducing the risk of hypertension (HT) complications, control of blood pressure (BP) levels remains inadequate. Dihydropyridine calcium channel blockers show antihypertensive effect due to significant vasoselective action with a minimal impact on a conductive system of the heart....
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Столичная издательская компания,
2015-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_d97c5b74416b40f18d6b71ce64d01e5d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a E. EL. Trisvetova |e author |
| 245 | 0 | 0 | |a THE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONS |
| 260 | |b Столичная издательская компания, |c 2015-09-01T00:00:00Z. | ||
| 500 | |a 1819-6446 | ||
| 500 | |a 2225-3653 | ||
| 500 | |a 10.20996/1819-6446-2015-11-2-202-208 | ||
| 520 | |a Despite progress in reducing the risk of hypertension (HT) complications, control of blood pressure (BP) levels remains inadequate. Dihydropyridine calcium channel blockers show antihypertensive effect due to significant vasoselective action with a minimal impact on a conductive system of the heart. Lercanidipine is a dihydropyridine calcium channel blocker of the third generation with high lipophilicity and long-lasting action. Lercanidipine had shown both in monotherapy and in combination with ACE inhibitors or angiotensin II blockers the good antihypertensive effect with stable BP profile throughout the day, organoprotection that slowed down the progression of HT complications, metabolic neutrality and safety in mild to moderate HT. | ||
| 546 | |a EN | ||
| 546 | |a RU | ||
| 690 | |a arterial hypertension | ||
| 690 | |a complications | ||
| 690 | |a calcium channel blockers | ||
| 690 | |a lercanidipine | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Diseases of the circulatory (Cardiovascular) system | ||
| 690 | |a RC666-701 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 202-208 (2015) | |
| 787 | 0 | |n https://www.rpcardio.online/jour/article/view/153 | |
| 787 | 0 | |n https://doaj.org/toc/1819-6446 | |
| 787 | 0 | |n https://doaj.org/toc/2225-3653 | |
| 856 | 4 | 1 | |u https://doaj.org/article/d97c5b74416b40f18d6b71ce64d01e5d |z Connect to this object online. |